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Multiple activations of individual genes during embryonic liver and HCC development have repeatedly prompted
speculations about conserved embryonic signatures driving cancer development. Recently, the emerging discussion
on cancer stem cells and the appreciation that generally tumors may develop from progenitor cells of diverse
stages of cellular differentiation has shed increasing light on the overlapping genetic signatures between
embryonic liver development and HCC. However there is still a lack of systematic studies investigating this area. We
therefore performed a comprehensive analysis of differentially regulated genetic signaling pathways in embryonic
and liver cancer development and investigated their biological relevance.
Genetic signaling pathways were investigated on several publically available genome wide microarray experiments
on liver development and HCC. Differentially expressed genes were investigated for pathway enrichment or
underrepresentation compared to KEGG annotated pathways by Fisher exact evaluation. The comparative analysis
of enrichment and under representation of differentially regulated genes in liver development and HCC
demonstrated a significant overlap between multiple pathways. Most strikingly we demonstrated a significant
overlap not only in pathways expected to be relevant to both conditions such as cell cycle or apoptosis but also
metabolic pathways associated with carbohydrate and lipid metabolism. Furthermore, we demonstrated the clinical
significance of these findings as unsupervised clustering of HCC patients on the basis of these metabolic pathways
displayed significant differences in survival.
These results indicate that liver development and liver cancer share similar alterations in multiple genetic signaling
pathways. Several pathways with markedly similar patterns of enrichment or underrepresentation of various
regulated genes between liver development and HCC are of prognostic relevance in HCC. In particular, the
metabolic pathways were identified as novel prognostically relevant players in HCC development.Introduction
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide and its incidence is rising [1,2].
In contrast to other cancers, therapeutic options other
than surgery remain very limited, and it was only three
years ago that a drug, sorafenib, first showed a benefit in
patient survival [3] Thus, exploring the genetic mechan-
isms leading to HCC development warrants being* Correspondence: teufel@uni-mainz.de
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reproduction in any medium, provided the orfurther evaluated, especially with respect to the identifi-
cation of novel drug targets.
It has repeatedly been reported that several genes are
relevant to both embryonic liver development and liver
cancer. Recently, several studies on liver embryonic devel-
opment have established the concept that the genetic pro-
grams controlling liver development are often deregulated
in liver cancer. Signaling transductory pathways including
Wnt-signaling pathway [4-9], TGF-β signaling pathway
[10-12], MAPK signaling pathway [13,14], Jak-STAT sig-
naling pathway [15,16], Notch signaling pathway [17,18],
and the Hedgehog signaling pathway [19,20] have been
reported to play important roles in hepatoblastLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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opment, as well as in hepatocarcinogenesis. Since many
biological mechanisms such as cell cycle control, growth
and proliferation are essential to both embryonic devel-
opment and cancer de-differentiation, this may not be
completely surprising. A pioneer study analysed a com-
prehensive microarray data set of mouse liver develop-
ment during multiple stages. Li et al. reported that genes
enhanced in early stages of liver development are also
enriched in HCC development [21-23].
There has been renewed interest in these observations
over recent years as they would be in accordance with a
cancer stem cell hypothesis for hepatocellular carcinoma.
Although such a stem cell hypothesis is still a matter of
debate, it has been repeatedly documented that solid
tumors contain a small subgroup of tumorigenic cells
which can generate new tumors in xenograft transplant-
ation [24]. This subpopulation was termed cancer stem
cells since they possess stem cell-like properties and con-
tribute to a hierarchical structure containing varied pro-
genies [25]. Simultaneously, fetal liver-derived hepatic
stem/progenitor cells over expressing Bmi1 or mutant B-
catenin may acquire enhanced self-renewal capability and
tumorigenicity to initiate HCC [26]. Finally, unsupervised
clustering of patients with HCC based on their gene ex-
pression profiles show that patients with HCC and gene
expression profiles similar to hepatic stem/progenitor cells
had a poorer prognosis [27,28]. Together, it is clear that
liver carcinogenesis shares common genetic programs
with liver development. However, systematic analysis of
genetic signaling pathways or genetic signatures essential
to both embryonic development and cancer had not previ-
ously been performed.
Thus, studying liver development may not only be valu-
able from an embryologic perspective but also to contrib-
ute to a better understanding of the pathogenesis of liver
cancer. Deciphering common molecular events may be
useful for unraveling regulatory mechanisms which can
impact on cancer diagnosis and treatment, and separate
them from regulated but non-essential bystander genes.
In the absence of a systematic, genome wide comparison
of genetic expression profiles and genetic pathways, we
performed such an analysis based on the pathway annota-
tion of the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database [29,30] curated pathways (http:www.
genome.jp/kegg/pathway.html). Furthermore, we evalu-
ated enriched or underrepresented pathways for their rele-
vance with respect to prognosis of patients with HCC.
Results
Enriched signaling pathways in mouse liver development
Multiple genes have been identified to be differentially
regulated during liver development [21-23]. However,
only scant data is available on the interaction of thesegenes. Since we had earlier pointed out that liver devel-
opment is unlikely to be due to only a few individual
master regulators, one has to assume a complex inter-
action of genetic networks drive liver development [31].
We have therefore analyzed the regulation of signaling
pathways in liver development using microarray datasets
from embryonic mouse liver development over multiple
time points (GSE13149 and GSE11201), microarray
datasets of two murine HCC models (GSE8642 and
GSE9012), and a human HCC datatset containing
micrarray data from 139 HCC patients [27,31]. KEGG
contained a total of 258 pathways. Of these, 174 (67%)
pathways were deregulated in at least one developmental
stage. The pathway category “signaling molecules and
interaction” emerged to be the most frequently altered
cellular biological process in liver development, as it was
deregulated in 80% (61/76) of all investigated embryonic
stages (p-value ranged between 3.5e-32 and 0.04).
Furthermore, genes of the “ECM-receptor interaction
pathway” were enriched among genes differentially regu-
lated during liver development and most of these genes
were upregulated with highest enrichment of up-
regulated genes in perinatal and postnatal stages (p-value
ranged between 4.6e-05 and 0.04).
“Cell growth and death” related signaling pathways
were deregulated in 57% (43/76) of investigated stages
and developmental arrays, with the subcategories “cell
cycle” and “p53 signaling pathway” to be enriched in dif-
ferentially regulated genes during liver development with
up-regulation of “cell cycle” in embryonic and perinatal
stages and “p53 signaling pathway” in almost all stages
of liver development (p-value ranged between 5.6e-38
and 3.4e-07, and between 9.8e-07 and 0.02, for cell cycle
and p53 signaling pathway, respectively).
Major deregulations were observed in metabolic sig-
naling pathways. Among those, “nucleic acid metabol-
ism” was the most often altered metabolic process
during liver development, as it was deregulated in 84%
(32/38, p-values ranging between 7.0e-09 and 0.02) over
all time points and developmental arrays followed by
“lipid metabolism” and “carbohydrate metabolism”.
“Lipid metabolism” and “carbohydrate metabolism” were
deregulated in 63% (192/304, p-values ranging between
4.4e-10 and 0.05) and 54% (164/304, p-values ranging
between 9.5e-08 and 0.05) of all developmental stages,
respectively. In contrast to the former pathways showing
enrichment during liver development, most genes of
these metabolic signatures were down-regulated. Down-
regulation of many lipid-related pathways including
androgen and estrogen metabolism (p-value ranged be-
tween 0.0001 and 0.05), fatty acid metabolism (p-value
ranged between 1.2e-08 and 0.04), bile acid biosyn-
thesis (p-value ranged between 1.7e-06 and 0.03) and
carbohydrate-related pathways including ascorbate and
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0.02), pentose and glucuronate interconversions (p-value
ranged between 2.4e-06 and 0.009) was observed in
almost all stages during liver development among path-
ways with the highest enrichment in down-regulated genes
in almost all developmental stages.Enriched signaling pathways in Hepatocellular carcinoma
Out of the 258 KEGG curated pathways, 119 were
deregulated in at least one liver cancer array. Since the
Lee [27,32] dataset deminstrated at least two subgroups
of patients we investigated the enrichment of signalling
pathways also for genes deregulated only in 20% (Lee20)
or 50% (Lee50) of patients. The pathway category “sig-
naling molecules and interaction” was the most affected
biological process in HCC, as it was deregulated in 75%
(Lee20: 9/12) or 50% (Lee50: 6/12), with the “ECM-
receptor interaction” pathway being the most frequently
up-regulated pathway in HCC. It was up-regulated in
100% (Lee20: 3/3, Lee50: 3/3) malignant cancer arrays in
both human and mice (p-value ranged between 1.0e-05
and 0.02).
Furthermore, the pathway category “cell growth and
death” was deregulated in 44% (Lee20: 4/9) and 22%
(Lee50: 2/9) of malignant cancer arrays with “cell cycle”
being the most frequently altered pathway of this KEGG
subcategory as it was enriched in differentially regulated
genes in 67% (lee20: 2/3) and 33% (Lee50: 1/3) malig-
nant cancer arrays (p-value ranged between 3.8e-05 and
0.03) followed by “p53 signaling pathway” (p-value equal
to 0.003).
Metabolic pathways were also identified to be altered
in HCC. The pathway category “lipid metabolism” was
the most affected metabolic process in HCC, as it was
deregulated in 46% (Lee20: 22/48) and 33% (Lee50: 16/
48) of malignant cancer arrays followed by “carbohydrate
metabolism” category, deregulated in 38% (Lee20: 18/48)
and 33% (Lee50: 16/48). Down-regulation of affected
genes was the major trend of regulation in these meta-
bolic processes. “Linoleic acid metabolism” emerged the
most frequently deregulated lipid-related metabolic
pathway, as it was deregulated in all liver cancer arrays
(p-value ranged between 2.4e-06 and 0.03) followed by
“fatty acid metabolism” (p-value ranged between 1.1e-10
and 0.03), “androgen and estrogen metabolism” (p-value
ranged between 0.0002 and 0.002), and “bile acid biosyn-
thesis” (p-value ranged between 4.5e-06 and 0.01). For
the carbohydrate-related metabolic pathways, “pentose
and glucuronate interconversions” appeared to be the
most frequently deregulated pathways, as it was deregu-
lated in 100% (Lee20: 3/3, Lee50: 3/3) malignant cancer
arrays (p-value ranged between 2.2e-05 and 0.02) fol-
lowed by “ascorbate and aldarate metabolism” (p-valueranged between 0.0004 and 0.02), and “butanoate metab-
olism” (p-value ranged between 2.2e-08 and 0.03).
These results were further validated in a second,
human HCC dataset (Additional file 1: Table S7) [33].
We confirmed the pathway category “signaling mole-
cules and interaction” to be the most enriched biological
process in human HCC. Furthermore, we also confirmed
a significant enrichment of established cancerogenic
pathways such as “Cell cycle”, “p53 signaling pathway”,
or “ECM-receptor interaction”. Besides these already
established cancer related pathways, we again demon-
strated an enrichment of signaling pathways related to
lipid and carbohydrate metabolism.
Commonly enriched signaling pathways in hepatocellular
carcinoma and liver development
Investigating genetic signaling pathways in both embry-
onic liver and HCC development, we were able to dem-
onstrate that it is not only single genes that may be
differentially regulated in both conditions but also that
there is a significant overlap between enriched signaling
pathways in liver development and HCC. Of the 258
pathways listed in the KEGG database, a total of 112
(43%) pathways were deregulated in at least one malig-
nant cancer array and one developmental array. Most of
the pathways already reported above to be enriched in
either liver or HCC development were also overlapping
in enrichment between these two conditions.
The pathway category of “signaling molecules and
interaction” was the most enriched cellular process in
liver development and liver cancer, as it was deregulated
in 75% (Lee20: 9/12) and 50% (Lee50: 6/12) of malignant
cancer arrays and in 80.3% (61/76) over 19 developmen-
tal arrays across diverse developmental stages. As
demonstrated in Figure 1, the overlap / similarity with
respect to these pathways in liver development and HCC
development was obvious.
Furthermore, we not only demonstrated an enrich-
ment of signaling pathways related to ECM-receptor but
even more we were able to demonstrate that the inter-
action of these mechanisms were highly conserved in
malignant cancer arrays as well as in embryonic develop-
mental arrays. The ECM-receptor interaction pathway was
deregulated in 100% (Lee20: 3/3, Lee50: 3/3) malignant
cancer arrays and in 68,4% (13/19) developmental arrays,
suggesting a high relevance of the mechanisms that govern
extracellular matrix-transmembrane molecule interactions
in both liver cancer and liver development.
Next, several signaling pathways which can be sum-
marized mainly as being essential to lipid metabolism
and carbohydrate metabolism were the most affected
metabolic processes in HCC, as they were deregulated in
46% (Lee20: 22/48) or 33% (Lee50: 16/48) and 38%
(Lee20: 18/48) or 33% (Lee50: 16/48) of malignant
Figure 1 Summary of signaling pathways with highest overlap of enrichment of differentially regulated genes during embryonic liver
and HCC development. Each grey square at the grid intersection between pathway and developmental stage represents a significant
enrichment (black circuits) or under re-presentation (white circuits) of differentially regulated genes of this pathway in the analyzed data set.
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olism they were the most significantly altered metabolic
processes in liver development with lipid metabolism
being deregulated in 63% (192/304) of investigateddevelopmental arrays and carbohydrate metabolism in
54% (164/304) of developmental arrays. Down-
regulation of multiple genes in many lipid-related path-
ways could not only be detected by means of
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on the basis of individual genetic signaling pathways
such as “androgen and estrogen metabolism”, “bile acid
biosynthesis”, “fatty acid metabolism”, and “linoleic acid
metabolism” as well as down-regulation of carbohydrate-
related pathways such as “ascorbate and aldarate metabol-
ism”, “pentose and glucuronate interconversions”, and
“propanoate metabolism” observed to be highly conserved
in malignant cancer arrays and in almost all developmental
stages and arrays.
Finally, the pathway category of “cell growth and
death” was seen to be altered in developmental arrays
with “cell cycle”, and “p53 signaling” pathway, being
deregulated in almost all stages during liver develop-
ment, while in malignant cancer arrays “cell cycle” being
the most frequently deregulated pathway of this signal-
ing pathway category. It was deregulated in 67%
(Lee20: 2/3) or 33% (Lee50: 1/3) of liver cancer arrays.
Intersection of Genes within Pathways between human
HCC Liver samples and mouse samples is shown in
Additional file 2: Tables S1-S4 and P-value and
observed/expected ratio range for each Pathway in Add-
itional file 2: Table S5.
Survival / Biological relevance
Since we were able to demonstrate a significant overlap
in specific categories of genetic signaling pathways, espe-
cially “signaling molecules”, “cell growth and death”,
“lipid metabolism” and “carbohydrate metabolism”
(Figure 1), we next analyzed the potential biological rele-
vance of these signatures in a data set of 139 human
HCC [27,32]. The pathways for “signaling molecules”,
“lipid metabolism”, and “carbohydrate metabolism” in
particular lacked previous investigation. All four signa-
tures were demonstrated to define prognostically rele-
vant subgroups of HCC by means of unsupervised
clustering on the basis of differential regulation of the
genes of these specific signatures (Figures 2, 3, 4, 5).
Of all 712 genes associated with signaling pathways of
the category “signaling molecules”, 57 were demon-
strated to be regulated more than 1.5 fold in at least 20%
of data and less than 5% of data missing. Unsupervised
clustering of 139 patients with HCC on the basis of
these genes resulted in two prognostically diverse sub-
groups (p = 0.001, adj p-value 0.003, R-index 0.75, indi-
cating agreement between clustering results on 1000
randomly perturbed data sets, where Gaussian noise was
added to the log-gene expression measurements) sug-
gesting a biological relevance of this genetic signatures
with respect to survival.
Of the 254 genes associated with signaling pathways of
the category “cell growth and death”, 33 were demon-
strated to be regulated with the same criteria of regula-
tion. Unsupervised clustering of 139 patients with HCCon the basis of these genes also resulted in two prognos-
tically diverse subgroups (p = 0.0005, adj p-value 0.002,
R-index 0.8). These findings support an essential role of
“cell growth and death” associated genes and signaling
pathways with respect to survival.
Most interestingly, we identified for the first time an im-
portant role of metabolic signaling pathways in HCC. 343
genes were associated with signaling pathways of the cat-
egory “lipid metabolism”. Of these, 116 were demon-
strated to be regulated more than 1.5 fold in at least 20%
of data and less than 5% of data missing. Of 309 genes
associated with signaling pathways of the category “carbo-
hydrate metabolism”, 104 were demonstrated to be regu-
lated given the same criteria. Unsupervised clustering of
139 patients with HCC on the basis of both these meta-
bolic categories of signaling pathways resulted in two
prognostically distinct subgroups (lipid metabolism:
p= 0.006, adj p-value 0.011, R-index 0.93; carbohydrate
metabolism: p= 0.013, adj p-value 0.013, R-index 0.99).
These data confirmed for the first time a significant role
of the comprehensive number of metabolic signaling path-
ways in HCC with respect to survival.
High cluster reproducibility for all four signatures was
demonstrated by an R-index between 0.75 and 0.99
based on 1000 perturbations [34].
Discussion
In the past, several individual genes were shown to be
differentially regulated in liver development and HCC.
For example, many of the pathways summarized by
Lemaigre [35] to be essential to apoptotic and growths
mechanisms during liver development were previously
also reported to play essential roles in tumor develop-
ment [9,12,14,16,20]. In a larger biological context this
seems reasonable as multiple general biological mechan-
isms are common to both liver development and liver
cancer, such as cell cycle regulation, tissue growth or
regulation of apoptosis. The multiple reports available
on individual genes called for a systematic study on
commonly differentially regulated genetic patterns rele-
vant to both liver development and HCC. However, such
a systematic review on either individual genes or super-
imposed signaling pathways is still lacking.
In order to gain substantial insight in relevant overlap-
ping biological mechanisms involved in embryonic liver
and cancer development, we performed a comprehensive
analysis of differentially regulated genetic signaling path-
ways in both conditions. The identification of genetic net-
works regulating HCC development and the course of
disease are of significant importance as they may not only
provide deeper insight into the underlying biology but also
point towards novel therapeutic targets. Furthermore, the
intersection between liver development and liver growth
may aid in identifying driver genes truly involved in these
Figure 2 Kaplan Meier estimated survival for the subgroups identified by unsupervised clustering of 139 patients with HCC based on
the pathway category “signaling molecules and interaction”. Clustering resulted in two prognostically distinct groups (group A contained 82
patients and group B contained 57 patients; p-values were determined by log-rank test).
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stander genes being differentially regulated in one of these
conditions but not essential to the biological mechanisms
fundamental to liver development or cancer growths.Figure 3 Figure shows Kaplan Meier estimated survival for the subgr
HCC based on the pathway category “cell growth and death” demon
patients and group B contained 55 patients; p-values were determineMost strikingly, we were able to demonstrate for the
first time a substantial overlap between signaling path-
ways involved in embryonic liver development and liver
cancer development. Of the 258 pathways listed in theoups identified by unsupervised clustering of 139 patients with
strated two prognostically distinct groups (group A contained 84
d by log-rank test).
Figure 4 Based on the expression profile of genes associated with the carbohydrate metabolism, Kaplan Meier estimated survival
resulted in two prognostically distinct groups. These subgroups were identified by unsupervised clustering of 139 patients with HCC based
on the pathway category “carbohydrate metabolism” (group A contained 78 patients and group B contained 61 patients; p-values were
determined by log-rank test).
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pathways were deregulated in at least one malignant
cancer array and one developmental array. Among the
signaling pathways showing enrichment of differentiallyFigure 5 Besides Carbohydrate metabolism, the lipid metabolism was
expression profile of genes associated with the lipid metabolism, Kaplan M
These subgroups were identified by unsupervised clustering of 139 patient
A contained 68 patients and group B contained 71 patients; p-values wereregulated genes were several pathways, which we would
have anticipated being so, such as signaling molecules.
These biological mechanisms pathways were previously
demonstrated to be essential to cell cycle, cell divisionalso demonstrated to be of high relevance. Based on the
eier estimated survival resulted in two prognostically distinct groups.
s with HCC based on the pathway category “lipid metabolism” (group
determined by log-rank test).
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these pathways among the differentially regulated genes
demonstrated to be relevant to liver development and
HCC served as a control for the feasibility of our ap-
proach. In contrast, several signaling pathways that were
previously reported to be critical to tumor development
such as Wnt [9], Jak-Stat [14], MAPK [16], TGF beta
[12] and others [18,20] demonstrated an enrichment of
differentially regulated genes in only a few individual
array experiments but not a significant or high overlap
to genetic pathways enriched in embryonic development
of the liver. A more detailed view on pathway regulation
with respect to the diverse ethnic background of patients
in the human data set (78 Caucasian, 61 Chinese) [32]
may identify even more enriched pathways.
However, our analysis of overlapping signaling path-
ways between liver development and HCC development
shed light on novel biological aspects of tumor develop-
ment as these mechanisms demonstrated a high conser-
vation throughout embryonic growths and multiple
HCC array experiments.
It was only in the past few years that a significant rele-
vance of metabolic mechanisms in cancer biology was
recognized. With respect to carbohydrate metabolism
indications came from clinical studies demonstrating
that patients with diabetes mellitus have a higher inci-
dence in HCC development and also its presence wor-
sens the prognosis of an existing HCC [38,39]. Similarly
the community is beginning to realize that other meta-
bolic changes may contribute to cancer biology. With re-
spect to lipid metabolism almost no experiments have
been performed or published so far. The only study
touching the subject demonstrated that the risk of HCC
in patients with chronic hepatitis C increases in propor-
tion to BMI in a wide range of its values, from under-
weight to obese [40].
Although from a clinical perspective this link between
metabolic disease and cancer must be regarded as being
reliable, the underlying molecular mechanisms remain
elusive and have only marginally been studied. Our ex-
tensive screen for enriched and conserved pathways be-
tween liver development and liver cancer pointed
towards a significant role of carbohydrate and lipid me-
tabolism in both conditions. These two metabolic path-
way categories were among the most enriched signaling
pathways among all KEGG curated pathways. Besides
speculations about the biological meaning of this broad
overlap such as an involvement in stem cell biology (see
below), these observervations called for an analysis of
their medical relevance for the development and prog-
nosis of HCC. We were able to demonstrate a relevance
of both metabolic pathways “lipid metabolism” and
“carbohydrate metabolism”. Unsupervised clustering of
these patients on the basis of differentially genesenriched in either carbohydrate or lipid metabolism,
resulted in a separation of two significantly diverse sub-
groups showing significantly distinct survival. Thus, we
furthermore confirmed a biological significance of our
findings with respect to a systems biology view on meta-
bolic pathways. This also defined novel characteristic
and prognostically relevant biological mechanisms which
would be worth exploring further in future experiments.
Viewing our results in a more general context of can-
cer development, these results may also shed light onto
the upcoming discussion on embryonic stem cells and
the state of differentiation in liver cancer.
During recent years these observations have been of
renewed interest as they would go along well with a can-
cer stem cell hypothesis for hepatocellular carcinoma.
However, such a stem cell hypothesis is still a matter of
debate [41]. Our results showed broadly overlapping
genetic mechanisms leading to the biological changes
during embryonic liver development and HCC. However,
the question whether these signatures were re-activated
in previously differentiated cells or whether they repre-
sent an early developmental stage during stem/progenitor
cell differentiation requires further investigation. In any
case, our data support a strong link between embryonic
liver and liver cancer development.
Conclusion
Together, we demonstrated for the first time a signifi-
cant overlap between genetic signaling pathways, and
therefore biological mechanisms, between liver cancer
and embryonic liver development using a comprehensive
systems biology approach to pathway analysis of genome
wide microarray data. The pathway categories with high-
est overlap in enrichment of regulated genes not only
pointed out common biological mechanisms, but were
demonstrated to provide novel prognostically relevant
genetic signatures in HCC. In particular, metabolic path-
ways relating to carbohydrate or lipid metabolism had




Murine microarray datasets from experiments studying
the development of HCC were retrieved from the GEO
database (http:www.ncbi.nih.gov/geo/, Table 1). All stud-
ies had been performed using the Affymetrix MG 430
2.0 chips (http://www.affymetrix.com). The GSE13149
dataset provided gene expression profiles during embry-
onic development at days E11.5, E12.5, E13.5, E14.5,
E15.5, E16.5, E17.5, and E18.5 days post conception
(dpc) as well as day0, day3, day7, day14, day21 postnatal.
These data were compared to gene expression profiles of
normal adult mouse liver tissues (18 weeks). In the
Table 1 Microarray datasets used in this study
GEO Identifier Description No. of arrays Microarray platform Reference
GSE13149 Mouse liver development; time series 26 Affymetrix Mouse Genome 430 2.0 Array [21]
GSE11201 Mouse liver development; time series 14 Affymetrix Mouse Genome 430 2.0 Array -
GSE9012 Trim24/TIF1-alpha knockout mouse HCC
model; liver samples
10 Affymetrix Mouse Genome 430 2.0 Array [42]
GSE8642 Mdr-2 knockout mouse HCC model;
liver samples
12 Affymetrix Mouse Expression 430A Array -
GSE1898 / GSE4024 Human HCC; liver samples 139 NCI/ATC Hs-OperonV2 [27,32]
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onic development at days E10.5, E11.5, E12.5, E13.5,
E14.5, E16.5 days post conception (dpc) is compared
with normal adult liver (10 weeks). Finally, gene expres-
sion profiles of HCC specimens taken from Mdr-2
knockout mice and Trim24 knockout mice were com-
pared to adjacent liver tissues and normal liver taken
from wild type littermates, respectively.
The gene expression data set for studying gene expres-
sion in human HCC contained 139 [27,32] 70-mer oligo
microarrays consisting of 21 329 genes, which were pro-
duced at the Advanced Technology Center at the Na-
tional Cancer Institute. The dataset includes two ethnic
groups (61 Chinese and 78 white) with 73.3% male indi-
viduals. The median duration of follow up was
23.4 months and the median age 57. As reference for all
microarray experiments pooled RNA from 19 normal
livers was used.
Microarray data normalisation
All gene expression data for mouse datasets were nor-
malized by computing the RMA (Robust Multichip
Average) [43] directly from Affymetrix CEL files of em-
bryonic mouse liver tissues, mouse liver tumor tissues
and adult mouse normal liver tissues. The Bioconductor
package (R-package) containing the RMA implementa-
tion “affy” was installed by accessing the biocLite.R
script directly from the Bioconductor website (http:
www.bioconductor.org/biocLite.R). Normalized data
from human HCC microarrays was generated by median
over array normalization.
Selection of differentially regulated genes
Using the FTP annotation files for mouse genome (ftp://
ftp.genome.ad.jp/pub/kegg/genes/organisms/mmu) and
human genome (ftp://ftp.genome.ad.jp/pub/kegg/genes/
organisms/hsa) from the KEGG PATHWAY DATABASE
(http://www.genome.jp/kegg/), a list of KEGG associated
genes was identified. KEGG-related genes with expres-
sion values at least twofold higher or at least twofold
lower between human liver tumor and human normal
liver samples, mouse tumor liver and normal mouse
liver samples, and mouse embryonic (and after birth,developing) liver and adult mouse liver samples were
selected as differentially regulated genes.
KEGG pathway analysis
A functional gene enrichment analysis was performed
based on the KEGG listed pathways [29,30]. Whether
the percentage of genes with altered expression in a cer-
tain pathway differed from the percentage of altered
genes not represented in the pathway was tested by
Fisher exact test. KEGG pathways with at least two dif-
ferentially regulated genes and a p-value of < 0.05 were
considered “enriched”. As the Fisher Exact tests were
only used as a tool to select enriched pathways for fur-
ther analyses, no adjustment for multiple testing was
performed. Since the Lee dataset demonstrated at least
two subgroups of patients we investigated the enrich-
ment of signalling pathways also for genes deregulated
only in 20% (Lee20), 50% (Lee50), 70% (Lee70) or 80%
(Lee80) of patients. Results were confirmed in a second
human HCC dataset [33].
Evaluation of the biological relevance of highly
overlapping genetic signaling pathways in human
hepatocellular carcinomas
To investigate the prognostic relevance of the individual
genetic signaling pathway signatures in HCC, we ana-
lyzed a comprehensive data set containing 139 genome
wide HCC tissue microarrays [27,32]. Gene names (Add-
itional file 2: Table S6) and identifiers were retrieved
from the KEGG database. Initial data analysis was made
using the BRB array tools (http://linus.nci.nih.gov/BRB-
ArrayTools.html). Initially, all genes with a percentage of
missing data exceeding 5% and fold-change <1.5 were
excluded from further analysis. Next, an unsupervised
clustering was performed on the basis of the gene list
summarizing all genes being differentially regulated
within the pathway category to be investigated
(Additional file 3: Figure S8 shows related heatmaps).
Hierarchical cluster analysis was perfomed using cen-
tered correlation and average linkage available in BRB
Array Tools. Cluster reproducibility analysis with 1000
perturbations were realized to measure the proportion
of pairs of specimens within a cluster (R-index) [34].
Becker et al. Molecular Cancer 2012, 11:55 Page 10 of 11
http://www.molecular-cancer.com/content/11/1/55This clustering split the human data set into two
subgroups A and B. To compare the difference in sur-
vival between these subgroups, Kaplan-Meier survival
analysis and log-rank test were used. The analysis was
performed by using the MedCalc software packages
(http://www.medcalc.be).
Additional files
Additional file 1: Table S7: KEGG Pathway Analysis on a second
human HCC of Microarray-Set GSE25097 [33]. Each grey square at the
grid intersection between pathway and developmental stage represents
a significant enrichment (black circuits) or under re-presentation (white
circuits) of differentially regulated genes of this pathway in the analyzed
data set.
Additional file 2: Table S1: Intersection of Genes within Pathways
between human HCC Liver samples and mouse samples (GSE13149,
murine HCC: Trim24 knockout mice and Mdr2 knockout mice) for
the pathway category “Carbohydrate Metabolism”. Table S2:
Intersection of Genes within Pathways between human HCC Liver
samples and mouse samples (GSE13149, murine HCC: Trim24 knockout
mice and Mdr2 knockout mice) for the pathway category “Lipid
Metabolism”. Table S3: Intersection of Genes within Pathways between
human HCC Liver samples and mouse samples (GSE13149, murine HCC:
Trim24 knockout mice and Mdr2 knockout mice) for the pathway
category “Cell Growth and Death”. Table S4: Intersection of Genes within
Pathways between human HCC Liver samples and mouse samples
(GSE13149, murine HCC: Trim24 knockout mice and Mdr2 knockout mice)
for the pathway category “Signaling Molecules and Interaction”. Table S5:
P-value and observed/expected ratio range for each Pathway. Table S6:
Genes used for survival calculation.
Additional file 3: Figure S8: Corresponding heatmaps to the Kaplan
Meier estimated survival (Figures 2, 3, 4, 5).
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